These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 7002280)

  • 1. The importance of the stable category for chemotherapy treated patients with advanced and relapsing prostate cancer.
    Slack NH; Mittelman A; Brady MF; Murphy GP
    Cancer; 1980 Dec; 46(11):2393-402. PubMed ID: 7002280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [The evaluation of chemotherapy of relapse in prostatic cancer with new response criteria].
    Isaka S; Fuse H; Akaza H; Moriyama N; Usami M; Kotake T; Matsumura Y; Imai K; Yamanaka H; Matsumoto K
    Hinyokika Kiyo; 1987 Sep; 33(9):1389-95. PubMed ID: 3434494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic factors in patients with prostate cancer refractory to endocrine therapy: univariate and multivariate analyses including doubling times of prostate-specific antigen and prostatic acid phosphatase.
    Akimoto S; Inomiya H; Akakura K; Shimazaki J; Ito H
    Jpn J Clin Oncol; 1997 Aug; 27(4):258-62. PubMed ID: 9379515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Response criteria for prostatic cancer treated by chemotherapy or antiandrogenic therapy].
    Akaza H; Usami M; Kotake T; Matsumura Y; Moriyama N; Imai K; Fuse H; Isaka S; Yamanaka H; Matsumoto K
    Hinyokika Kiyo; 1987 Jun; 33(6):894-904. PubMed ID: 3673839
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A reexamination of the stable category for evaluating response in patients with advanced prostate cancer.
    Slack NH; Brady MF; Murphy GP
    Cancer; 1984 Aug; 54(3):564-74. PubMed ID: 6375857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Response criteria for the prostate of the USA National Prostatic Cancer Project.
    Murphy GP; Slack NH
    Prostate; 1980; 1(3):375-82. PubMed ID: 7279807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stable versus partial response in advanced prostate cancer.
    Slack NH; Brady MF; Murphy GP
    Prostate; 1984; 5(4):401-15. PubMed ID: 6377284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    Scott WW; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Saroff J; Murphy GP
    J Urol; 1976 Aug; 116(2):211-3. PubMed ID: 950706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemotherapy for hormone-refractory prostate cancer.
    Shelley M; Harrison C; Coles B; Staffurth J; Wilt TJ; Mason MD
    Cochrane Database Syst Rev; 2006 Oct; (4):CD005247. PubMed ID: 17054249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of patients with advanced prostatic cancer to administration of somatostatin analog RC-160 (vapreotide) at the time of relapse.
    González-Barcena D; Schally AV; Vadillo-Buenfil M; Cortez-Morales A; Hernández L V; Cardenas-Cornejo I; Comaru-Schally AM
    Prostate; 2003 Aug; 56(3):183-91. PubMed ID: 12772187
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific acid phosphatase versus acid phosphatase in monitoring patients with prostate cancer.
    Killian CS; Vargas FP; Slack NH; Murphy GP; Chu TM
    Ann N Y Acad Sci; 1982; 390():122-32. PubMed ID: 6953924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Treatment for hormone-refractory or relapsing prostatic cancer].
    Hirao Y; Ozono S; Okajima E
    Gan To Kagaku Ryoho; 1996 Mar; 23(4):418-26. PubMed ID: 8678492
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decade of experience with chemotherapy for prostate cancer.
    Slack NH; Murphy GP
    Urology; 1983 Jul; 22(1):1-7. PubMed ID: 6346631
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of continued androgen-deprivation therapy and other prognostic factors on response and survival in phase II chemotherapy trials for hormone-refractory prostate cancer: a Southwest Oncology Group report.
    Hussain M; Wolf M; Marshall E; Crawford ED; Eisenberger M
    J Clin Oncol; 1994 Sep; 12(9):1868-75. PubMed ID: 8083710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma.
    Eisenberger MA; Simon R; O'Dwyer PJ; Wittes RE; Friedman MA
    J Clin Oncol; 1985 Jun; 3(6):827-41. PubMed ID: 2409240
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of long-term administration of Tegafur on patients with relapsing advanced carcinoma (stage D) of the prostate].
    Yoshida K; Negishi T; Kobayashi N; Saito T; Owada F; Ajima J; Satake I; Tari K
    Hinyokika Kiyo; 1983 Jan; 29(1):105-11. PubMed ID: 6428191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of advanced prostate cancer with cyclophosphamide, doxorubicin, and methotrexate.
    Straus MJ; Fleit JP; Engelking C
    Cancer Treat Rep; 1982 Oct; 66(10):1797-802. PubMed ID: 7127321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The continued evaluation of the effects of chemotherapy in patients with advanced carcinoma of the prostate.
    Scott WW; Gibbons RP; Johnson DE; Prout GR; Schmidt JD; Saroff J; Murphy GP
    Trans Am Assoc Genitourin Surg; 1976; 68():24-8. PubMed ID: 1030548
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy for localized, high-risk prostate cancer.
    Narayan S; Smith DC; Sandler HM
    Semin Radiat Oncol; 2003 Apr; 13(2):152-7. PubMed ID: 12728444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is there a role for chemotherapy in nonmetastatic prostate cancer?
    Keizman D; Eisenberger M
    Curr Opin Support Palliat Care; 2010 Sep; 4(3):141-6. PubMed ID: 20613534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.